Across TCGA pan-cancer cohorts, TACSTD2 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated TACSTD2 data layer compared with 23 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in testicular germ cell tumors (TGCT), where higher TACSTD2 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated TACSTD2 expression acts as an unfavorable survival marker.

TGCT and ACC are the cancer types where TACSTD2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
TGCT	DFS	Median	All	0.002	0.837	<.001	6	view →
ACC	DFS	Median	All	0.195	0.748	.003	3	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

Exploration

Same gene, other analysis: TACSTD2 tumor-vs-normal RNA expression · all TACSTD2 data types